Here’s what you should know:
1. CRH Medical is a healthcare services company that focuses primarily on acquiring practices in the gastroenterology anesthesia space.
2. SeekingAlpha cited its drastic revenue growth to $100 million in 2017 from $8 million in 2013 as an example of its success to date.
3. CRH has also grown its free cash flow from $2 million to $26 million over the same time period.
4. The publication believes CRH could go from its $3.35 per share price to as high as $7 per share by the end of 2018.
5. However, investing in the company is not without risk. Bad healthcare investor sentiment and CMS reimbursement policy changes could undercut CRH greatly. Investors are also leery of the company’s staying power as noninvasive tests like Exact Sciences’ Cologuard are developed.
However, the fears related to Cologuard may be overblown because patients that are flagged by Cologuard must undergo a colonoscopy to confirm a diagnosis.
More articles on anesthesia:
Here’s how physician pay is changing as insurers nix fee-for-service — 6 thoughts
SurgCenter ASC joins Anthem’s Medicare Advantage provider network — 3 insights
Even Aflac can’t duck data breaches: Health plan incident among 29 reported in May
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.